Video Experimental Relacionado
Updated: Feb 24, 2026
12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
10.9K
Enfermedades Ampollosas Autoinmunes: Actualización Terapéutica
Michael Kasperkiewicz1, Nina van Beek2, Enno Schmidt3,4
1Division of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, USA.
Drugs
|February 23, 2026
Resumen
Esta revisión resume ensayos clínicos recientes para enfermedades ampollosas autoinmunes (EAA), centrándose en el penfigoide ampolloso y el pénfigo. Si bien las nuevas terapias son prometedoras, persisten los desafíos en el desarrollo de tratamientos eficaces para estas raras afecciones.
Área de la Ciencia:
- Dermatología; Inmunología; Reumatología
Sus antecedentes:
- Las enfermedades ampollosas autoinmunes (EAA) son trastornos raros y heterogéneos.; Caracterizados por autoanticuerpos dirigidos contra proteínas estructurales en la piel y epitelios.; Incluye enfermedades de pénfigo y penfigoide con bajas tasas de incidencia.
Objetivo del estudio:
- Revisar ensayos aleatorizados controlados (EAC) recientes para EAA.; Discutir opciones de tratamiento futuras para EAA comunes.; Destacar el panorama actual del tratamiento y las necesidades insatisfechas.
Principales métodos:
- Se resumieron los resultados de EAC para inmunoadsorción, rilzabrutinib, efgartigimod, dupilumab, benralizumab, mepolizumab y avdoralimab.; Se incluyeron datos de guías nacionales e internacionales.; Se incorporó la experiencia de los autores y las aprobaciones recientes de la FDA.
Principales resultados:
- Dupilumab aprobado para penfigoide ampolloso moderado/grave.; Rituximab autorizado para pénfigo vulgar.; Algunos ECIR recientes fracasaron, lo que indica desafíos en el desarrollo de terapias para EAA.
Conclusiones:
- La autorización de rituximab y dupilumab marca avances terapéuticos.; La falta de ensayos y los EAC fallidos resaltan la necesidad de mejores terapias.; El desarrollo de tratamientos eficaces y seguros para EAA sigue siendo un desafío.
Videos de Conceptos Relacionados
01:29Inflammatory Bowel Disease IV: Pharmacological Management
837
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
837
01:29Autoimmune Disorders
2.0K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
2.0K
01:14Myocarditis III: Medical Management
251
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
251
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
633
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
633
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
591
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
591
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
565
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
565